---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-017546"
form_type: "8-K"
ticker: "STEX"
cik: "0001530766"
company_name: "Streamex Corp."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:25:43.911128+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BioSig Technologies appoints Chris Baer to board of directors

## Summary
- Chris Baer appointed as director effective May 2, 2024; term expires at next annual meeting.
- Baer brings over 25 years commercial experience in medical devices; current CCO at CDL Nuclear Technologies.
- He will serve on audit, nominating, and compensation committees.
- Previously held VP/GM roles at St. Jude Medical/Abbott and VP of Commercial Operations at Impulse Dynamics.

## SEC filing metadata
- accession: 0001493152-24-017546
- form_type: 8-K
- ticker: STEX
- cik: 0001530766
- company_name: Streamex Corp.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1530766/000149315224017546/0001493152-24-017546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1530766/000149315224017546/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-017546
- JSON: https://secwatch.observer/filing/0001493152-24-017546.json
- Plain text: https://secwatch.observer/filing/0001493152-24-017546.txt

## Key facts
- Executive change
  Chris Baer was appointed as director at Streamex Corp..
  - Action: appointed
  - Role: director
  source text: On May 2, 2024, the board of directors of BioSig Technologies, Inc. (the “Board”) appointed Mr. Chris Baer as a director on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1530766/000149315224017546/0001493152-24-017546-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.